Publicaciones científicas

SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

24-dic-2022 | Revista: Clinical Translational Oncology

Maria Gonzalez-Cao  1 , Teresa Puertolas  2 , Clara Martinez-Vila  3 , Cristina Carrera  4 , Cayetana Maldonado Seral  5 , Pedro Rodríguez-Jiménez  6 , Silvia Sequero  7 , Pablo Cerezuela-Fuentes  8 , Rosa Feltes Ochoa  9 , Eva Muñoz  10   11 , Mónica Antoñanzas Basa  12 , Juan Martín-Liberal  13 , Ainara Soria  14 , Juan Francisco Rodriguez Moreno  15 , Ivan Marquez-Rodas  16 , Pilar Lopez Criado  17 , José Luis Manzano  18 , Rafael Lopez-Castro  19 , Pablo Ayala de Miguel  20 , Laura Villalobos  21 , Salvador Martin Algarra  22 , Ines Gonzalez-Barrallo  23 , Aram Boada  24 , Almudena García Castaño  25 , Susana Puig  4 , Guillermo Crespo  26 , Pablo Luna Fra  27 , Cristina Aguayo Zamora  28 , Marta Feito Rodríguez  9 , Lara Valles  29 , Ana Drozdowskyj  30 , Jesús Gardeazabal  31 , Luis Antonio Fernandez-Morales  32 , Alberto Rodrigo  33 , Raquel Cruz  34 , Oriol Yelamos  35 , Belen Rubio  36 , Karmele Mujica  37 , Mariano Provencio  38 , Alfonso Berrocal  39 ; Spanish Melanoma Group (GEM)


Background: The Spanish Melanoma Group (GEM) developed a national registry of patients with melanoma infected by SARS-CoV-2 ("GRAVID").

Methods: The main objective was to describe the COVID-19 fatality rate in patients with melanoma throughout the pandemic, as well as to explore the effect of melanoma treatment and tumor stage on the risk of COVID-19 complications. These are the final data of the register, including cases from February 2020 to September 2021.

Results: One hundred-fifty cases were registered. Median age was 68 years (range 6-95), 61 (40%) patients were females, and 63 (42%) patients had stage IV. Thirty-nine (26%) were on treatment with immunotherapy, and 17 (11%) with BRAF-MEK inhibitors. COVID-19 was resolved in 119 cases, including 85 (57%) patients cured, 15 (10%) that died due to melanoma, and 20 (13%) that died due to COVID-19. Only age over 60 years, cardiovascular disorders, and diabetes mellitus increased the risk of death due to COVID-19, but not advanced melanoma stage nor melanoma systemic therapies. Three waves have been covered by the register: February-May 2020, August-November 2020, and December 2020-April 2021. The first wave had the highest number of registered cases and COVID-19 mortality.

Conclusion: Tumor stage or melanoma treatments are non-significant prognostic factors for COVID-19 mortality. During the pandemic in Spain there was a downward trend in the number of patients registered across the waves, as well as in the severity of the infection.

CITA DEL ARTÍCULO Clin Transl Oncol. 2023 Mar;25(3):768-775. doi: 10.1007/s12094-022-02985-7. Epub 2022 Dec 24.